Vivos Therapeutics, Inc. (VVOS) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Vivos Therapeutics, Inc., a Delaware corporation, with a report date of August 20, 2026. The company is headquartered in Littleton, Colorado, and its common stock trades on The NASDAQ Stock Market LLC under the symbol VVOS.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a specific corporate event rather than periodic financial results.
Material Changes and Events
- Item 7.01 (Regulation FD Disclosure): On August 20, 2026, the company issued a press release announcing the opening of a new testing and treatment facility.
- The press release is included as Exhibit 99.1 and is incorporated by reference, though the specific details of the facility's capacity or location are not detailed in the cover page text.
Guidance, Outlook, and Risks
The filing text does not provide specific guidance, outlook, management commentary, or risk factors beyond the announcement of the new facility. The document explicitly states that the information furnished pursuant to Item 7.01 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific details regarding the new testing and treatment facility, including location, operational capacity, and expected impact on the business.
- Verify the company's current cash position and funding status to assess the ability to sustain operations while expanding facilities, as this 8-K does not contain financial statements.
- Monitor subsequent filings for any updates on the facility's regulatory approvals or commercial launch timeline.